• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

    91.75 +0.72 (+0.79%)
    Streaming Delayed Price Updated: 2:35 PM EST, Feb 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about GeneDx Holdings Corp. - Class A Common Stock

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    News headline image
    New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
    From GeneDx
    Via Business Wire
    News headline image
    Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
    Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
    Via Benzinga
    News headline image
    Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results ↗
     
    Via Benzinga
    News headline image
    The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts ↗
     
    Via Benzinga
    News headline image
    GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics ↗
    The company provides sequencing tools to help diagnose children with rare diseases. 
    Via Investor's Business Daily
    News headline image
    Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance ↗
    GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue. 
    Via Benzinga
    News headline image
    Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    Expert Ratings For GeneDx Hldgs ↗
     
    Via Benzinga
    News headline image
    The Latest Analyst Ratings For GeneDx Hldgs ↗
     
    Via Benzinga
    News headline image
    GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
    From GeneDx
    Via Business Wire
    News headline image
    Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
    From GeneDx
    Via Business Wire
    News headline image
    The Markets Are Ignoring Risk, But That Does Not Mean You Should... ↗
    It is Fall clean-up time. Sell lagging and sagging companies. 
    Via Talk Markets
    News headline image
    GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx to Participate in Fall Investor Conferences
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From GeneDx
    Via Business Wire
    News headline image
    WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 ↗
    WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
    From GeneDx
    Via Business Wire
    News headline image
    GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing ↗
    GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
    Via Benzinga
    News headline image
    GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
    From GeneDx Holdings Corp.
    Via GlobeNewswire
    News headline image
    7 Small-Cap Stocks With Massive Potential Returns ↗
    Explore these small-cap stocks with high potential in health care, REITs, entertainment, hardware, finance, and distribution industries. 
    Via InvestorPlace
    News headline image
    GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
    From GeneDx Holdings Corp.
    Via GlobeNewswire
    News headline image
    Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying ↗
     
    Via Benzinga
    News headline image
    GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
    From GeneDx Holdings Corp.
    Via GlobeNewswire
    News headline image
    Over $4M Bet On ProFrac Holding? Check Out These 3 Stocks Insiders Are Buying ↗
     
    Via Benzinga
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.